SCHEMBL23748367

SCHEMBL23748367

O=C(Nc1cnc(-c2ccc(-c3nc4ccc(Cl)cc4o3)cc2)cn1)C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.44
TP53 P04637 1/20 0.44
CASP3 P42574 4/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SENP7 Q9BQF6 3/20 0.43
POLB P06746 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
FASN P49327 1/20 0.43
MET P08581 1/20 0.43
CETP P11597 6/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
HDAC6 Q9UBN7 1/20 0.40
SENP8 Q96LD8 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
TTR P02766 1/20 0.39
ALB P02768 1/20 0.39
MAOA P21397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30965486 1.00 MAPT (0.44) MAPTTP53CASP3NPC1RAB9A
SCHEMBL23748369 0.87 RAB9A (0.56) MAPTTP53CASP3NPC1RAB9A
SCHEMBL30965467 0.87 RAB9A (0.56) MAPTTP53CASP3NPC1RAB9A
SCHEMBL23748362 0.83 CASP3 (0.59) MAPTTP53CASP3NPC1RAB9A
SCHEMBL30965495 0.82 NPC1 (0.47) MAPTNPC1RAB9AKMT2AMEN1
SCHEMBL25045581 0.82 NPC1 (0.47) MAPTNPC1RAB9AKMT2AMEN1
SCHEMBL30965476 0.82 CASP3 (0.58) MAPTTP53CASP3NPC1RAB9A
SCHEMBL24106590 0.82 CASP3 (0.58) MAPTTP53CASP3NPC1RAB9A
SCHEMBL23748364 0.74 CASP3 (0.72) MAPTTP53CASP3NPC1RAB9A
SCHEMBL23748380 0.73 CASP3 (0.71) MAPTTP53CASP3NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113195084-B Benzoxazoles and related compounds useful as modulators of chaperone mediated autophagy 阿尔伯爱因斯坦医学院 2024-04-09 CN claimed
US-20210387953-A1 BENZOXAZOLE AND RELATED COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS ALBERT EINSTEIN COLLEGE OF MEDICINE 2021-12-16 US claimed
EP-3863755-A1 BENZOXAZOLE AND RELATED COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS Albert Einstein College of Medicine (US) 2021-08-18 EP claimed
CN-113195084-A Benzoxazoles and related compounds useful as modulators of molecular chaperone-mediated autophagy 阿尔伯爱因斯坦医学院 2021-07-30 CN claimed
US-20240156872-A1 Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations ALBERT EINSTEIN COLLEGE OF MEDICINE 2024-05-16 US disclosed
WO-2023018801-A1 COMPOSITIONS AND METHODS OF ENRICHING HEMATOPOIETIC STEM CELL POPULATIONS AND METHODS OF USE THEREOF ALBERT EINSTEIN COLLEGE OF MEDICINE (US) 2023-02-16 WO disclosed
US-20210387953-A1 BENZOXAZOLE AND RELATED COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS ALBERT EINSTEIN COLLEGE OF MEDICINE 2021-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240156872-A1 Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations SQSTM1, MCL1, HSPA2 MAPT 2357/4885TP53 166/4885CASP3 1753/4885
US-20210387953-A1 BENZOXAZOLE AND RELATED COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS CLPX, SQSTM1, ATG7 MAPT 976/4885TP53 2276/4885CASP3 2371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.